Show simple item record

dc.contributor.advisorDachs, Gabi
dc.contributor.authorMontecillo , Jaya Ysabelle
dc.date.available2019-11-08T04:05:06Z
dc.date.copyright2019
dc.identifier.citationMontecillo , J. Y. (2019). Gene Modification of Breast Cancer Cells for Cancer Imaging (Thesis, Bachelor of Biomedical Sciences with Honours). University of Otago. Retrieved from http://hdl.handle.net/10523/9779en
dc.identifier.urihttp://hdl.handle.net/10523/9779
dc.description.abstractHuman epidermal growth factor receptor 2 (HER2) is a prominent breast cancer cell surface receptor that is overexpressed in approximately 20-30% of breast cancer tumours. Trastuzumab (Herceptin) is an effective clinical treatment against HER2-positive breast cancer, but ineffective against HER2-negative breast cancer. Current imaging methods may not be adequate to detect heterogenous HER2 expression in breast cancer tumours. MARS molecular CT is a new whole-body imaging technology that has potential to detect this variability non-invasively. This study aimed to produce genetically modified murine breast cancer cells that over-express human HER2 protein to develop a preclinical HER2-positive animal model to assess the potential of MARS molecular CT in measuring HER2 protein expression in tumours non-invasively. Murine breast cancer cell lines EO771 and Py230 were genetically modified using lipid-based transfection technology and DNA plasmid vectors encoding the full-length human HER2. Stable transfectants were selected via a selection marker co-expressed in the plasmid vectors. HER2 protein expression in the modified cancer cells were analysed by western blot analysis. HER2 protein localisation was visualised using immunofluorescence and compared to human HER2-positive human breast cancer cells (SkBr3) and parental non-transfected murine breast cancer cells. The optimised transfection protocol for the murine breast cancer cell lines resulted in up to 67% of EO771 and 56% of Py230 cells transfected. This optimised transfection protocol allowed the production of a series of gene-modified clones that showed varying levels of HER protein expression and cellular localization. Overall, this project has produced murine breast cancer cells that express the human HER2 protein. These HER2 modified cell lines will be used to develop a mouse model of HER2-positive breast cancer that will be used to assess the potential of MARS imaging technology in measuring HER2 protein expression in vivo.
dc.language.isoen
dc.publisherUniversity of Otago
dc.rightsAll items in OUR Archive are provided for private study and research purposes and are protected by copyright with all rights reserved unless otherwise indicated.
dc.subjectHER2
dc.subjecttransfection
dc.subjectgene-modification
dc.subjectbreast cancer
dc.subjectmouse
dc.subjectEO771
dc.subjectPy230
dc.subjectmouse cancer cells
dc.subjecttransfection optimisation
dc.titleGene Modification of Breast Cancer Cells for Cancer Imaging
dc.typeThesis
dc.date.updated2019-11-08T03:53:45Z
dc.language.rfc3066en
thesis.degree.disciplinePathology Department
thesis.degree.nameBachelor of Biomedical Sciences with Honours
thesis.degree.grantorUniversity of Otago
thesis.degree.levelHonours
otago.interloanyes
otago.openaccessAbstract Only
 Find in your library

Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item is not available in full-text via OUR Archive.

If you would like to read this item, please apply for an inter-library loan from the University of Otago via your local library.

If you are the author of this item, please contact us if you wish to discuss making the full text publicly available.

This item appears in the following Collection(s)

Show simple item record